A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year followup study of 164 patients
P. Chevalet et al., A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year followup study of 164 patients, J RHEUMATOL, 27(6), 2000, pp. 1484-1491
Objective. (1) To evaluate the corticosteroid sparing effect of an initial
intravenous (iv) pulse of mcthyl-prednisolone (MP) in the treatment of simp
le forms of giant cell arteritis (GCA), (2) To analyze corticosteroid respo
nse, steroid related side effects, and GCA complications.
Methods. Patients received a 240 mg iv pulse of MP followed by 0.7 mg/kg/da
y oral prednisone (Group 1), or 0.7 mg/kg/day prednisone without an iv puls
e (Group 2, controls), or a 230 mg iv pulse of MP followed by 0.5 mg/kg/day
prednisone (Group 3). Corticosteroid dosage was reduced after normalizatio
n of 2 biological inflammatory variables to obtain half-dosage after 3 week
s in Groups 1 and 2 and 20 mg/day after 2 weeks in Group 3. Tapering was sy
stematically attempted from the 6th month of treatment.
Results, One hundred sixty-four patients were included in the trial (1992-9
6). Cumulative doses of corticosteroids after one year were identical for a
ll groups (p = 0.39). No significant differences were observed in the time
required for normalization of C-reactive protein, corticosteroid resistance
(13.5%), and corticosteroid related side effects (39% of patients; p = 0.3
7). Corticosteroid resistant patients received larger doses and showed a hi
gh risk of GCA related complications (p = 0.02).
Conclusion. MP pulses have no significant longterm, corticosteroid sparing
effects in the treatment of simple forms of GCA and should be limited to co
mplicated forms. Moreover, corticosteroid resistance is a real risk; factor
for GCA complications.